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▪ Investment Thesis: We value Canopy Growth 
(T.WEED) at C$46.90 FY 19 vs. today’s price of C$39.28, 
representing an annualized return of 19.4%. We expect 
Canopy Growth to lead the newly opened recreational 
market in Canada given its strong capacity of supply. 
▪ Potential Catalysts: 19 clinical trials on the 
pipeline including a Phase III insomnia trial and international 
regulatory reforms for medical cannabis on the way in more 
than 20 countries. 
▪ Constellation Brands: Constellation Brands’ C$5 
billion cash injection puts Canopy Growth on the forefront to 
gain a dominant position both in the Canadian recreational 
and international medical market. Having 12 times more 
cash than any of its competitors combined, Canopy Growth 
has a strong first mover advantage due to its ability to tap 
into new markets quickly and develop new products. 
▪ Looking Beyond Canada: Europe’s rising star in 
the medical cannabis, Germany, has imported 1,268 kg of 
medical cannabis from Canada since the beginning of the 
year, with Canopy dominating 46% of the volume. We 
expect the German market to develop at a fast pace in the 
upcoming year. 
▪ A Leader in Capacity: Canopy Growth is among 
the best placed cannabis producers to supply demand, with 
2.4 million sqf in production facilities and a capacity of 
production growing at a CAGR of 198% in 2 years.  
 
  
“CANOPY GROWTH” COMPANY REPORT 
 
 
 
  PAGE 2/32 
 
 
 
Table of Contents 
1. BIRTH OF AN INDUSTRY ....................................................................... 3 
2. COMPANY OVERVIEW ........................................................................... 5 
2.1 COMPANY DESCRIPTION ............................................................................. 5 
▪ General Information .................................................................. 5 
▪ Revenue and Production Capacity .......................................... 5 
▪ Sales Strategy ........................................................................... 6 
▪ Market Development ................................................................. 6 
2.2 SHAREHOLDER STRUCTURE ....................................................................... 7 
3. PRODUCT ANALYSIS ............................................................................ 8 
4. CANADIAN MEDICAL MARKET .......................................................... 10 
4.1 HISTORICAL AND CURRENT MARKET......................................................... 10 
4.2 POTENTIAL MARKET AND DEVELOPMENT .................................................. 11 
4.3 MARKET SHARE AND MARKET PLAYERS ................................................... 12 
5. INTERNATIONAL MEDICAL MARKET ................................................ 14 
5.1 HISTORICAL AND CURRENT MARKET......................................................... 14 
5.2 POTENTIAL MARKET AND DEVELOPMENT .................................................. 15 
5.3 MARKET SHARE AND AND MARKET PLAYERS ............................................ 16 
6. RECREATIONAL MARKET .................................................................. 17 
6.1 HISTORICAL AND CURRENT MARKET......................................................... 17 
6.2 POTENTIAL MARKET AND DEVELOPMENT .................................................. 18 
6.3 MARKET SHARE AND AND MARKET PLAYERS ............................................ 20 
7. FINANCIAL ANALYSIS ......................................................................... 22 
7.1 COST OF GOODS SOLD ............................................................................. 22 
7.2 OPERATING EXPENSES ............................................................................. 22 
▪ General & Administrative and Sales & Marketing ................ 22 
▪ Research and Development ................................................... 23 
▪ Operating Profit........................................................................ 24 
7.3 INVESTED CAPITAL .................................................................................... 24 
▪ Working Capital ....................................................................... 24 
▪ Capital Expenditures ............................................................... 25 
8. VALUATION ........................................................................................... 26 
8.1 COST OF CAPITAL ..................................................................................... 26 
8.2 DISCOUNTED CASH FLOWS....................................................................... 26 
8.3 SCENARIO ANALYSIS ................................................................................. 27 
8.4 SENSITIVITY ANALYSIS .............................................................................. 27 
9. RISK FACTORS ..................................................................................... 28 
FINANCIAL STATEMENTS ....................................................................... 29 
REPORT  RECOMMENDATIONS ........................................................................ 30 
 
  
“CANOPY GROWTH” COMPANY REPORT 
 
 
 
  PAGE 3/32 
 
 
 
1. Birth of an Industry 
Historically in Western culture, cannabis consumption has been considered taboo, 
yet today, society is experiencing the first boom days of the cannabis industry as 
a result of a shift in perspective: the war on drugs has failed for marijuana as 
millions of people are still consuming it, there is increasing public support for 
legalisation (for example, in the US, 64% of Americans back legalisation versus 
12% in 19691), the medical benefits of the components of cannabis are starting to 
be understood and accepted and there is a growing perception that regulation can 
better protect public health by enforcing safety requirements.  
Cannabis has been used as a form of medical treatment since 400 A.D.2 and was 
common in the 19th century, although its use soon diminished with the development 
of drugs (which were preferred due to their standardisation, testing and 
accessibility, while cannabis could vary in quality and potency3) and with the 
classification of cannabis as a narcotic under the United Nations Single Convention 
on Narcotic Drugs (1961). Scientific research emerged in the 1970s uncovering 
the potential beneficial effects of cannabinoids, in particular, tetrahydrocannabinol 
(“THC”) and cannabidiol (“CBD”), on the human body. Evidence suggests THC 
may help with nausea and vomiting, reducing pain and increasing appetite and 
may be effective in treating multiple sclerosis, while CBD offers relief in cases of 
epileptic seizures4, as concluded by the U.S. Food and Drug Administration5. 
These positive outcomes have helped pave the way to medical legalisation in 
Canada, first through the courts when in 2000, the Ontario Court of Appeal ruled 
cannabis prohibition to be unconstitutional because it did not provide for a medical 
use exemption and then through a series of  regulations: the Marihuana Medical 
Access Regulations in 2001 permitting personal cannabis cultivation, the 
Marihuana for Medical Purposes Regulations in 2013 allowing the privatisation of 
cannabis production, the 2015 ruling of the Supreme Court of Canada deciding to 
expand the legality of medical consumption to oils, foods and drinks and finally, 
with the 2016 current legal framework of the Access to Cannabis for Medical 
Purposes Regulations (“ACMPR”) authorising both licensed producers of cannabis 
(“LPs”) and individuals to grow cannabis for medical purposes and regulating sale. 
Internationally, around 20 countries have legalised medical marijuana treatments 
                                                 
1 McCarthy, J. (2017). Record-High Support for Legalizing Marijuana Use in U.S.. Gallup. 
2  Zias J, Stark H, Sellgman J, et al. Early medical use of cannabis. Nature. 1993;363:215 
3 Kalant, H. (2001), ‘Medicinal use of cannabis: history and current status’, Pain Research and 
Management 6, pp. 80-91.; Pisanti, S. and Bifulco, M. (2017), ‘Modern history of medical cannabis: from widespread use toprohibitionism and back’, Trends in 
Pharmacological Sciences 38 
4 NASEM (2017). The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies Press for the 
National Academies of Sciences. Engineering and Medicine. 
5 FDA News Release. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. (2018). 
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and another 6 are considering it. Each country has its own legislation determining 
conditions and requirements distinctively, while few countries regulate domestic 
cultivation (Denmark and Netherlands). Over the past few years, more and more 
countries are legalising marijuana medically and we expect this trend to continue, 
especially as countries are able to use Canada as a model. Practically, a regulated 
medical cannabis market means, for the patient, new beneficial and effective 
drugs, while for companies, considerable revenues acquired from patient sales, 
export and intellectual property (“IP”). The industry is constantly growing as more 
and more patients register for cannabis treatments, international markets are 
opening up and consumer preference is drifting towards higher-margin products 
(marijuana extracted products). Recreationally, cannabis became popular in the 
1960s6 and in recent years, in some countries, it has undergone depenalisation 
and reclassification as a softer drug. Due to several factors, such as the failure to 
prevent consumption, the rise in criminal records and government expenses for 
prosecutions of marijuana related convictions, Canada has legalised recreational 
cannabis consumption under the Cannabis Act on 17 October 2018. Although 
other countries have legalised, depanelised or adopted tolerant policies towards 
recreational marijuana, due to the unpredictability of the legalisation movement, 
we will not be considering international recreational consumption for the purposes 
of our report. Legalisation represents a big break for Canadian companies as 
recreationally, the possibilities are endless. Cannabis companies can derive 
revenues from sales (to the government-controlled stores or through private retail 
shops or online), developing value-added products (currently oils and softgel 
capsules but in 2019, other products such as cannabis infused beverages or 
edibles) and related IP rights, retail store experience and accessory products. The 
demand for marijuana has already existed in the illicit market and given competitive 
pricing and accessibility, these consumers (which have already been rising in 
numbers yearly) will be supplied by LPs (as further discussed in part 6). In addition, 
given that cannabis is more easily obtainable and will become easier to consume 
(in beverages or food for instance), it is expected that new consumers (not from 
the illicit market) will enter. Overall, we expect a significant development of both 
the global medical (excluding the United States) and the domestic recreational 
market, growing at a CAGR of 53% from C$2.1 billion in 2019 to C$ 26.3 billion. 
 
 
 
                                                 
6 Idem 1 
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2. Company Overview 
2.1 Company Description 
▪ General Information 
Canopy Growth Corporation (“Canopy Growth” or the “Company”) has been 
founded in 2013 in Ontario, Canada. It is a fully integrated company operating from 
seed to sale: cannabis production, medical and recreational sale and market 
development. The Company is currently traded on the Toronto Stock Exchange as 
WEED and on the New York Stock Exchange as CGC. The Company is currently 
managed by Bruce Linton, founder, chairman and co-chief executive officer, who 
was previously chief executive officer in a communication company and has been 
at the forefront of the legalisation movement in Canada, Mark Zekulin, president 
and co-chief executive officer, who was previously counsel for an international 
trade law firm and worked for the OECD and Tim Saunders, executive vice-
president and chief financial officer, who joined the Company in June 2015 having 
held executive finance positions in various large scale telecommunication 
companies. Canopy Growth currently has 24 subsidiaries, 20 of which are fully 
owned. Globally, it operates in 12 countries throughout 5 continents (Exhibit 2.1.1) 
and it employs 2,000 people as of September 2018 (versus less than 100 in Q1 
2016 (Exhibit 2.1.2)). 
▪ Revenue and Production Capacity 
So far, Canopy Growth has been servicing one third of all domestic medical sales 
and its revenues have grown exponentially, climbing from just C$2.3 million in 2015 
to C$77.9 million in 2018. We expect recreational sales of C$ 185 million in 2019, 
hence boosting the Company’s sales substantially. Furthermore, we expect 
recreational sales to grow at a compounded average growth rate (“CAGR”) of 42%, 
until 2025, compared to a CAGR of 88% for international medical sales, due to the 
medical legalisation momentum that is building up in more than 20 countries. 
Canopy Growth’s facilities count 2.4 million square feet (“sqf”) in production 
capacity, with plans to expand to 5 million sqf by the end of 2019 including over 
500.000 sqf of GMP (as defined in part 5) certified production space, this size 
permitting a production capacity of over 550,000 kilograms (“kg”) of cannabis each 
year. While Aurora Cannabis Inc. (“Aurora”) and Aphria Inc. (“Aphria”) are 
expected to be able to provide around 500,000 kg and 255,000 kg respectively. 
The Company’s capacity of production has been expanding (Exhibit 2.1.3), 
harvesting 15,217 kg in Q2 2019 from 1,711 kg in Q2 2017, thus growing at a 
CAGR of 198%. Aurora produced 4,996 kg in the last reported quarter, 70% fewer 
Exhibit 2.1.1 - Global presence 
Source: Company report 
Source: Company report 
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than Canopy Growth (Exhibit 2.1.3). Additionally, at the end of September 2018, 
Canopy Growth had 31,214 kg of dried flower, 21,499 liters of oil and 1,437 kg of 
softgel capsules in its inventory amounting for 23% of dried flower and 31% of oil 
of the total inventory of all Canadian LPs, according to governmental authority on 
health (“Health Canada”) (Exhibit 2.1.4 and Exhibit 2.1.5).  
▪ Sales Strategy 
The Company’s strategy towards recreational sales is to obtain as many supply 
agreements with as many provinces as possible (in order to provide the product to 
government established retail stores and in turn, to the consumer). So far, Canopy 
Growth has secured the highest number of supply agreements among its peers in 
terms of volume and is the only LP to have secured agreements with each territory 
and province in Canada. As concerns their private retails stores (only permitted in 
some provinces), the Company currently opened stores in Newfound and 
Labrador, Manitoba and Saskatchewan and soon in Alberta. We expect this 
number to reach 120 stores in 2025 due to their branding technique of attracting 
customers through the retail experience. In terms of international medical sales, 
the tactic is to go beyond simple supply to specific partners in countries having 
legalised medical cannabis prescriptions (as it is the case for some LPs), Canopy 
Growth instead intends to build local facilities in order to compete with domestic 
suppliers and export the produce in nearby locations.  
▪ Market Development 
Canopy Growth’s branding strategy is diversification: offering a wide range of 
products in different formats for diverse demographics. Despite regulatory 
limitations to advertising and labelling, the Company focuses on creating a shop 
experience such as Tweed and Tokyo Smoke which have gained popularity as 
lifestyle brands. Another method used by the Company is developing value-added 
products such as edibles, infused beverages and topicals with the help of its 
shareholder, Constellation Brands Inc. (“Constellation Brands”), an international 
producer and marketer of beer, wine and spirits (brand portfolio including Corona, 
Modelo and Svedka Vodka) which has an in-depth know-how of branding and 
advertising. In terms of IP, Canopy Growth has completed or acquired over 120 
patent filings across hardware, product formulation, genetics, product innovation 
and medical treatments through the acquisition of research and development 
(“R&D”) companies. The Company is also on level playing field with competitors in 
terms of drug development having launched clinical trials for pain and opioid 
dependence as well as insomnia. Nonetheless, one of the most significant 
competitive advantages of Canopy Growth is having 12 times more cash than any 
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of its Canadian competitors and almost as much cash on hand as the 
approximately US$7 billion that has been raised in the entire Canadian cannabis 
industry to date7, following the Constellation Brands cash injection of C$5 billion of 
October 2018. This readily available liquidity allows the Company to move quickly 
and capture market share early on by filing for patents, investing in product 
development or acquiring companies. In conclusion, we believe that Canopy 
Growth will continue to sustain a dominant market share in the cannabis industry 
due to its first mover advantage, large capabilities of production, close relationship 
to provinces, commitment to store experience enhancement and branding and 
product development, investment in research and clinical trials as well as its large 
available cash reserves. Their distinguishing feature is their leading position in all 
cannabis related services available, making it widely a diversified and deeply 
rooted company of this industry.  
2.2 Shareholder Structure 
The share capital of Canopy Growth is divided into 342.7 million shares, including 
the 105 million shares owned by Constellation Brands following the October 2018 
cash injection. The current market capitalisation of the Company is at C$13.4 
billion and the enterprise value at C$12.3 billion. The major shareholder of Canopy 
Growth is Constellation Brands, currently owning 38% of the shares (including 18.9 
million of deep in the money warrants) (Exhibit 2.2.1). Canopy has net cash of 
C$5.3 billion, on a pro forma basis. Cash injections into Canopy Growth include 
(1) the Constellation Brands October 2017 9.9% stake for C$245 million; (2) a 
January 2018 follow-on offering for C$201 million (8.8 million shares); (3) a C$600 
million June 2018 senior convertible notes issuance at 4.25%; and (4) the 
September 2018 Constellation Brands stake increase to 38% for C$5.1 billion. 
Additionally, If Constellation Brands exercises its potential warrants, its ownership 
could push above 50% and Canopy Growth would receive an additional C$5.5 
billion or more. Notable insider shareholders include Bruce Linton (Canopy 
Growth’s founder, chairman and co-CEO) who owns 0.75% of the Company and 
Murray Goldman (director) who owns approximately 1.1% of the shares. Other 
significant shareholders include the Vanguard Group, Morgan Stanley Canada, 
Horizons ETFs Management, each owning around 1% of the common shares. 
Additionally, Canopy Growth has a large retail investor shareholder base, 
corresponding to 32% of the share capital.  
 
                                                 
7 https://business.financialpost.com/cannabis/with-5-billion-constellation-deal-canopy-growth-is-emerging-as-the-google-of-pot  
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3. Product Analysis 
Canopy Growth has three distinctive line of products: dried flowers (Exhibit 3.1) 
being their core product and main source of revenue (which are the harvested 
whole flower after being dried to a specific moisture content and the stem and 
leaves after being trimmed, these can then be directly used in vaporiser or rolled 
in paper), cannabis oils (Exhibit 3.2) finally approved by Health Canada in 2016 
(which are the result of a thermal decarboxylation of the cannabis flower) and 
softgel capsules (Exhibit 3.3) introduced by the Company in 2017 (which are 
capsules filled with extracted cannabis resin in a dosed form). Together, cannabis 
oils and softgel capsules, represent one third of the Company’s sales in 2018. It is 
worth noting that softgel capsules are the preferred form of the plant for healthcare 
professionals due to their precise dosage and predictable effect. Other LPs have 
developed similar products, for instance, in August 2018, Aurora introduced its own 
softgel capsules8. However, other products are currently in development, these are 
value-added formats such as edibles (Exhibit 3.4), concentrates, infused 
beverages (Exhibit 3.5), topicals and vape pens. These products will only be 
available in the course of 2019 as the relevant regulatory framework is not yet in 
force9.  
The price per gram of dried flower in the medical sector, which is direct-to-
consumer, ranges between C$5 and C$15 depending on the brand, the quality and 
the potency whilst we estimate that the oil is sold at a premium of around 100-
160% compared to dried flower and softgel capsules at a premium of around 60-
200% compared to oil concentrate and equivalents. When comparing the average 
sale price per gram of different LPs in Exhibit 3.6, we have based ourselves on 
their total revenues divided by the kg sold, this is because available information 
from LPs mix a variety of different metrics and do not reveal a meaningful 
comparison. Canopy Growth’s average oil price per gram equivalent is 166% 
stronger than its average price per gram on dried flower (Exhibit 3.6). Compared 
to its main competitors, the Company has a much higher average sale price per 
gram of oil. This is because Canopy Growth’s extraction techniques allow it to 
obtain more liters of oil from a kg of dried flower, namely 8 liters per kg while its 
competitors typically range between 4 and 5 liters (Exhibit 3.8 and Exhibit 3.9). 
Canopy Growth is able to sell its gram of cannabis equivalent at a price of C$20,71 
which is 67% higher than the average and 133% higher than the lowest average 
                                                 
8 https://www.newswire.ca/news-releases/aurora-cannabis-obtains-health-canada-approval-for-softgel-capsule-production-at-aurora-vie-facility-and-
launches-cannimed-capsules-33-691482991.html 
9 Sec.gov. (2019). Aurora Cannabis Inc. Announces Results for the Fourth Quarter and 2018 Fiscal Year. [online] Available at: 
https://www.sec.gov/Archives/edgar/data/1683541/000106299318003989/exhibit99-202.htm  
Exhibit 3.3 – Softgel capsules 
Exhibit 3.2 - Oil 
Exhibit 3.1 Dried flower 
Source: Company website 
Source: Company website 
Source: Company website 
Exhibit 3.4 – Edibles 
Source: Company website 
Source: Company website 
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sale price (Exhibit 3.7). The average price per gram of Canopy Growth has been 
driven by production efficiency and consumer preference towards higher margin 
products (softgel capsules and oils), a consumption trend which we believe will 
continue in the future. This is because since 2016, the first-time oil derived 
products became available on the Canadian market, consumption has been 
increasing quarter to quarter and additionally, consumers can shift away from 
smoking (previously the only form of consumption available) which is a trend 
becoming less and less popular (smoking rate decreased from 25.9% in 2001 to 
16.2% in 201710). Nonetheless, using solely the average price per gram equivalent 
of oil is not representative of a comprehensive price analysis. A relevant aspect to 
consider is their efficiency in maximising CBD and THC yield (as these 
cannabinoids can vary in each gram). When highly efficient, the number of grams 
necessary to produce a given quantity of oil will be reduced due to the high yield, 
thereby making it cheaper for the producer while keeping oil prices the same for 
consumers, therefore resulting in a higher price per gram equivalent for the 
Company when compared to its competitors. Another aspect affecting pricing of 
oil products is the component ratio since products are diluted and therefore the 
quantity of THC/CBD or any active pharmaceutical component (“API”) is not 
equivalent to the quantity of the oil product itself. Therefore, we base ourselves on 
Canopy Growth’s revenues to calculate the price per milligram (“mg”) of any API 
which we have determined at C$0,17 (Exhibit 3.10), resulting in an average sale 
price per gram equivalent of dried flower of C$ 20,7 in the last reported quarter (Q2 
2019). Moreover, pricing can differ on whether the oil product is CBD or THC 
dominant (with the latter being cheaper as there are larger quantities of THC than 
CBD in the cannabis plant) thereby selling at a price range between C$90 to 
C$110. Generally, consumer inclination leans towards CBD dominant products as 
well as softgel capsules as a preferred product form (as reflected in 3.11 and 3.12). 
As the Company becomes increasingly more efficient in maximising CBD yield 
(further to acquisition of Ebbu LLC (“Ebbu”), a Colorado based R&D company 
which has the necessary know-how in this domain), prices will become more 
competitive for consumers and thereby further inclining demand towards CBD 
dominant products. Overall, we predict a 10% yearly decline in the average 
medical sale price per gram of dried flower due to lower cost of production, 
oversupply and increased competition, affecting the price from C$7,8 to C$4,0 in 
2025. Further to a down mark of 40% from the medical price to the wholesale 
                                                 
10 The Cannabis Act: The Facts - Government of Canada.  (2018). [online] Canada.ca. Available at: https://www.canada.ca/en/health-canada/news/2018/06/backgrounder-
the-cannabis-act-the-facts.html 
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recreational price per gram, we estimate a decrease from C$4,43 in 2019 to 
C$2,42 in 2025.  
In conclusion, we measure the average sale price per mg for all product forms to 
decrease at rate of 5% yearly over the forecasted period due to the same factors 
decreasing the price in medical sales (as explained above) but after having been 
offset by the higher demand of pricier CBD based products, the average sale price 
per mg of API will decline from C$0,17 in Q2 2019 to C$0,12 in 2025, which would 
result in an average sale price per gram equivalent of C$20,3 and C$14,9 
(wholesale price C$12,43 and $C 8,97). (Exhibit 3.13).  
4. Canadian Medical Market 
4.1 Historical and Current Market 
Since the development of research on the medicinal uses of cannabis (as 
discussed in part 1), it is commonly accepted that certain compounds of marijuana 
can help treat medical conditions and alleviate the negative symptoms of such 
conditions. Exhibit 4.1.1 presents the most prevalent medical conditions for which 
cannabis is usually prescribed. The legalisation of medical marijuana justifies this 
position and the ACMPR regulates the environment of cultivation, research and 
product development as well as patient treatment.  
For Canadian cannabis companies to medically sell this plant to patients, they 
must hold a license, issued by Health Canada, certifying their compliance under 
the ACMPR. The criteria for granting a license is linked to set security standards, 
facility standards, quality assurance standards and good product practices, 
amongst others11. The license will specify which of types of services the particular 
company is permitted to provide: cultivating with a view to sell (medically or 
recreationally), processing for cannabis products development, testing and 
researching12.  
In order for patients to obtain medical cannabis, they must contact a health 
practitioner or a specialised cannabis clinic, who will determine whether cannabis 
may be used to treat their respective symptoms by providing the patients with a 
medical document prescribing such use. With respect to insurance coverage, there 
has been some recent developments in terms of companies demanding insurers to 
extend coverage for medical marijuana for their employees, notably the grocery 
chain Loblaw. However, most insurers are cautious and are waiting for a drug 
                                                 
11 Cannabis Regulations - SOR/2018-144 - CONTROLLED DRUGS AND SUBSTANCES ACT - FOOD AND DRUGS ACT - CANNABIS ACT. (2018). Government of 
Canada. [online] Available at: https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-144/FullText.html 
12 Cannabis Licensing Application Guide. (2018). Government of Canada. [online] Available at: https://www.canada.ca/en/health-canada/services/drugs-
medication/cannabis/industry-licensees-applicants/licensing-summary.html 
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identification number (“DIN”) assignation and further research approved by Health 
Canada. In conclusion, insurers generally have limited reimbursement schemes to 
specific conditions and within strict monetary limits13.  
According to Health Canada, there are currently 342,103 registered medical 
cannabis patients in Canada14 (Exhibit 4.1.2). Since Q1 2016, registered patients 
have increased by a CAGR factor of 127%, therefore we can infer that demand 
has been significantly on the rise. In terms of this demand in volume, Health 
Canada estimates it to be around 60 tonnes for dried flower and oil in the last year 
(Exhibit 4.1.3). Oil sales have been the most popular with a CAGR of 657% from 
2016 to 2018, as opposed to dried flower which is at a CAGR of 68% over the 
same period (Exhibit 4.1.4). Overall, the total volume consumption in kg has been 
surging at a CAGR of 149% from 2016 to 2018. We believe this continuous hike is 
due to an increase in patient and doctor awareness due to positive media 
coverage, development of research and drugs and a trend leaning towards 
advantageous insurance healthcare plans.  In order to calculate the total current 
market value, we have used the Health Canada figures which resulted in an 
average consumption of 232 grams per patient yearly (obtained by dividing the 
yearly volume by the total number of patients) and an average yearly expenditure 
of C$1868 (obtained by using an average price of C$8,05) and thus concluding a 
total market value of C$468.5 million in 2018 with a volume of 58,216 kg.  
4.2 Potential Market and Development 
The legalisation of medical cannabis has led to the first steps towards clinical trials 
and research. Some examples include Canopy Growth’s testing of pain and opioid 
dependence; a Phase III (as explained below) Health Canada approved trial for 
insomnia15. Clinical trials lead to the development of new drugs by passing three 
phases: drug discover, efficacy confirmation, preclinical work (phase I, phase II 
and phase III) and Health Canada review16 and while there seems to be an 
extensive list of ongoing trials at various stages of the process17, the time duration 
from discovering to developing a drug takes on average 5 to 15 years. Costs are 
also high ranging from US$4 billion to as high as US$11 billion for drug 
development. Again, there have been some drug authorised cannabis medications 
such as Sativex for muscle spasticity from multiple sclerosis and Epidolex used to 
                                                 
13 Changing coverage for medical marijuana. (2017). Saskatchewan Pension Plan. [online] Available at: https://www.savewithspp.com/tag/din/ 
14 Cannabis market data. (2018). Government of Canada. [online] Available at: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/licensed-
producers/market-data.html 
15 Canopy Growth Corporation Reports Second Quarter Fiscal 2019 Financial Results. (2018) [online] https://www.prnewswire.com/news-releases/canopy-growth-
corporation-reports-second-quarter-fiscal-2019-financial-results-300750059.html 
16 Overview of the Clinical Trial Application Process - Health Canada. (2018). [online] Available at: https://www.canada.ca/en/health-canada/services/drugs-health-
products/drug-products/applications-submissions/guidance-documents/clinical-trials/overview.html 
17 Cannabis-med.org. (2018). Clinical Studies and Case Reports. [online] Available at: https://www.cannabis-med.org/studies/study.php?search=&sort=design 
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treat seizures resulting from with Lennox-Gastaut syndrome or Dravet syndrome18 
but this list could be much longer given significant progress in trials. Insomnia, for 
instance, is a condition that could potentially be eased using cannabis in the future 
and according to Prescient & Strategic Intelligence, this global market could 
generate US$28.6 billion by 202319. We believe that the untapped potential of the 
market relies primarily on the progress of clinical trials. So far most of the beneficial 
effects of the plan have not been discovered through scientific research but 
through positive patient feedback and surveys. Clinical trials would evidence the 
effects of the plant on various conditions and will increase awareness for 
physicians and patients alike. Moreover, hard data would incite the development 
of extraction-based drugs and their being awarded a DIN, in turn leading doctors 
to be more comfortable in their prescriptions and insurance companies more likely 
to cover costs for patients.  
We foresee that the medical demand will continue to grow steadily in terms of 
patient number to 450,000 by 2024 (Exhibit 4.1.5) with an average yearly 
consumption per patient growing at 2.5% CAGR yearly from 199 grams per patient 
in 2019, reaching a market value of C$967 million. For LPs, there are relatively 
large margins to be obtained in this sector as the sale is direct to consumer, instead 
of wholesale. Furthermore, product preference leans towards oils and softgel 
capsules (due to an increased awareness of the dangers of inhaling smoke) which 
also sustains higher margins. The expected development of clinical trials and 
standardisation of drugs will incite insurers to provide more extensive cover, 
thereby ensuring demand in the medical market.   
4.3 Market Share and Market Players 
Over the past three years, Canopy Growth has been capturing on average 25% of 
the patient share and 50% of product share of grams sold (although the historical 
average was 66.9%, we have replicated last year’s product share for the purpose 
of our valuation) of which 50% will come from oil and softgel based products by 
2025 substantiating patient preference towards these types of products. In terms 
of the number of patients, Canopy Growth has currently 84,400 registered patients, 
however this metric of patients is misleading as patients are able to register with 
several LPs, therefore we have used Health Canada numbers to calculate the 
above patient share. In terms of IP, Canopy Growth currently has 15 human clinical 
trials and 4 animal clinical trials ongoing (while competitor, Tilray has 6 clinical trials 
ongoing, Aurora 39 and Aphria do not have any pharmaceutical research ongoing). 
                                                 
18 Medical use of cannabis and cannabinoids. (2018). European Monitoring Centre for Drugs and Drug Addiction. 
19 Sleeping Aids Market by Offering – Global Market Size, Share, Development, Growth and Demand Forecast, 2013–2023. (2018). Prescient & Strategic Intelligence. 
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Overall, the Company has completed or acquired over 120 patent filings across 
hardware, product formulation, genetics, product innovation and medical 
treatments. The acquisition of Canopy Health Innovations (“CHI”) a cannabis 
research incubator focused on the R&D of cannabis drug formulation and dose 
delivery systems is evidence of the Company’s commitment to reinforce product 
development and research and further push IP patent filings. Furthermore, Canopy 
Animal Health (“CAH”) is a fully owned subsidiary of CHI and it focuses on 
cannabinoid science for pets. CAH has been approved the first veterinarian trial to 
study anxiety in mammals in August 2018. R&D expenses (as explained in the part 
7.2) further reflect the Company’s engagement in the medical research field, as we 
are predicting them to amount to 15% of medical sales by 2025, which is in line 
with the expenses of pharmaceutical companies. Once cannabis is declassified as 
a drug under Schedule 1 by the U.S. federal goverment, we believe that big 
pharmaceutical companies will be more likely to enter the market through 
partnerships with or acquisition of LPs and create more serious competition for 
these players. Although more relevant for the recreational market, we believe that 
branding will play an important role in the medical sector. Canopy Growth, through 
its subsidiary Spectrum, has patented colour-coded products in order to simplify 
dosage of CBD/THC and increase ease of prescription (Exhibit 4.1.6.). By 
opposition, Aphria, Aurora and Canntrust do not have a specific brand names for 
their medical products, instead they use their respective company names. Canopy 
Growth currently has a strong medical team, with the vice president, Amanda 
Daley, having spent 15 years in the pharmaceutical industry, having multiple roles 
at Pfizer, now in charge of the creation of medical education programs for 
healthcare professionals, and with the chief medical officer, Dr. Mark Ware, 
responsible for the research advancement of the Company, having served as the 
Director of Clinical Research at McGill University and acted as an advisor on 
medical cannabis policy for the Canadian government since 2001 and generally 
being recognised as a leader of medical cannabis research. Overall, we believe 
that the Company will be able to maintain its current medical market share, due to 
its first mover advantage, expertise and quality of their medical research team as 
well as being among the top cannabis companies in terms of numbers of IP related 
filings and licensing. Moreover, the strong marketing strategy, with the help of 
Constellation Brands in this department, can push its products further to 
physicians, patients and pharmacies alike. Canopy Growth is also at an advantage 
in terms of the cash reserves, as IP filings and drug development are expensive 
and smaller players are unlikely to afford these costs.  
 
Exhibit 4.1.6 Spectrum 
Source: Company website 
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5. International Medical Market 
5.1 Historical and Current Market 
While Canada has been a worldwide leader in medical cannabis exports since 
201620, relatively few countries have completely legalised the medical marijuana 
market. Despite this, there is a new trend toward medical legalisation (Exhibit 
5.1.1) and currently, over 20 other countries have legalised it medically. It is worth 
noting that each country takes a different regulatory position with variations on the 
types of medicine, insurance coverage and prescriptions. Germany is among the 
most sought after for Canadian cannabis companies due to its liberal medical 
market, no domestic cultivation and restricted personal cultivation. According to 
Farmako, a Frankfurt-based pharmaceutical company, the medical cannabis 
market in Germany is estimated at €19.1 million in 2018 and expected to reach 
€7.8 billion by 2028. Alternatively, Denmark is running a four-year test period 
permitting marijuana cultivation for licensed companies and thus some Canadian 
companies have already disclosed future joint projects with local companies. 
Overall, Farmako calculated the European market in 2018 to be at €59.3 million 
and is expecting it to grow to €55.2 billion by 2028. Cannabis is currently being 
traded across national borders for three reasons: medical purposes, clinical 
research and compassionate access. In order for Canadian companies to export 
marijuana to Europe, the importing country issues a good manufacturing practice 
(“GMP”) certification, meaning a set of rules ensuring the safety of consumption 
for food or drug products for a particular facility production site. Receiving such 
certification is the result of an on-site inspection which awards compliance under 
the legislation of the respective country. The exporting country’s health authority 
must issue an export permit for each individual shipment, which must be with a 
single partner in the importing country. Presently, the product being exported the 
most from Canada is dried flower, but we believe trends will shift towards oil and 
softgel as it is simpler for pateints and practitioners alike. Eventually a DIN 
identification number in Canada will further facilitate distribution as it will be easily 
assimilated with other pharmaceutical drugs. As concerns health insurance 
coverage, these vary from country to country, although insurance companies must 
justify rejections with a significant reason. In Germany, generally reimbursement 
is granted when patients are critically ill and doctors no longer see an alternative 
treatment (for example in palliative care for terminally ill patients) or in the 
                                                 
20 Idem 13 
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treatment of inflammatory diseases of the central nervous system (for example 
multiple sclerosis). Around two-thirds of cases are approved and although some 
appear as rejections, patients can resubmit in cases of incomplete applications21. 
5.2 Potential Market and Development 
The development of the market essentially relies on the speed of international 
medical legalisation which is impossible to accurately predict. Several factors could 
speed up the process, such as a proposal for MEPs within the European 
Parliament22 to vote the legal status of cannabis and its medical regulation in the 
EU and funding for scientific research23, a potential United Nations reclassification 
of the drug would also have a large impact on the market, positive media coverage 
such as “Nothing stopped her seizures until she found cannabis: Why the DEA just 
approved CBD drug for rare form of epilepsy” by CNBC24 can push towards inciting 
further scientific research and public interest and the award of DIN numbers for 
developed drugs further to the progress of clinical trials as discussed in part 4.2. 
Estimates of the value of the market vary from source to source, between C$9 
billion - C$200 billion. According to the ArcView Group, a US based market 
research company, the global medical spending will reach US$ 27 billion by 2027, 
with Europe likely becoming the largest medical cannabis market in the world, 
which Prohibition Partners, a UK consultancy firm specialised in the international 
cannabis industry, predicts to reach €55 billion by 2028 (given that all EU countries 
fully legalise medical cannabis). Europe is a popular export destination because 
there has been little legal development for domestic cultivation (except for 
Denmark and the Netherlands) therefore in an initial stage, it will be much more 
likely for these markets to rely on experienced cannabis producers for export. To 
forecast the international market, we selected the 31 countries where medical 
cannabis is legal or where regulatory templates are being built by governments. 
We have used United Nation’s 2025 population forecast for each country and 
ranked each country by gross domestic product per capita and compared them to 
Canada to estimate the projected annual consumer spending. To forecast the 
market value for 2025 we then applied a penetration rate of 1% of the total 
population in order to obtain the number of patients for each country and multiplied 
it by the projected consumer spending.  We then ranked each country, according 
to Canopy Growth’s ability to generate market share. In countries where Canopy 
                                                 
21 Thelocal.de. (2018). Medical marijuana in ‘high’ demand with over 13,000 applications: report. [online] Available at: https://www.thelocal.de/20180110/medical-
marijuana-in-high-demand-with-over-13000-applications-report 
22 Cannabis Europa. (2018). EUROPEAN PARLIAMENT SET TO VOTE ON MEDICAL CANNABIS RESOLUTION. [online] Available at: https://www.cannabis-
europa.com/en/news/2018/12/10/european-parliament-medical-cannabis 
23 DRAFT MOTION FOR A RESOLUTION. (2019). European Parliament. Committee on the Environment, Public Health and Food Safety.. [online] Available at: 
http://www.europarl.europa.eu/meetdocs/2014_2019/plmrep/COMMITTEES/ENVI/RE/2018/06-28/1155079EN.pdf 
24 CNBC. (2018). Why the DEA just approved a cannabis drug for rare childhood form of epilepsy. [online] Available at: https://www.cnbc.com/2018/09/27/cbd-science-
cannabis-provides-relief-to-children-with-rare-epilepsy.html 
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Growth has a presence, or where the Company is expected to be a first mover, we 
project a market share of 12%, whereas for the other countries we project a market 
share of 5% or 0% depending on the likelihood of the Company to partcipate in 
that market. In conclusion, our forecast gives an overall market share of 6.65% of 
the international market, translating into $C835 million in 2025. (Exhibit 5.2.1. and 
Exhibit 5.2.2.) 
5.3 Market Share and and Market Players 
Internationally, Canopy Growth is able to provide three types of services: exporting 
cannabis, building cannabis cultivation and sales facilities and advisory services. 
Canopy Growth can, as other cannabis companies, enter into supply partner 
agreements to export medical marijuana, subject to its legal compliance 
(discussed in part 5.1). The Company has currently entered into partner 
agreements to export medical cannabis to Australia, Brazil, the Czech Republic, 
Denmark, Germany (where it was the first Canadian company to export (through 
Spektrum Cannabis GmbH), accounting for 23.5% of all the exports made to 
Germany25) and Spain. Canopy Growth is also the first cannabis company to 
export cannabis in the U.S. for the purpose of medical R&D, a trade approved by 
the United States Drug Enforcement (DEA). One obstacle to export for smaller 
players are the cumbersome legal procedures of complying with the importing and 
exporting standards and the high cost of meeting GMP requirements for production 
facilities. Therefore, newer and smaller cannabis companies will struggle to 
overcome these impediments while Canopy Growth will find this less challenging 
due its large cash reserves. Another challenge of the international market is that 
in the long term, domestic production will be favoured in order to avoid export costs 
and ponderous procedures. Therefore, Canopy Growth’s strategy is to go beyond 
supply agreements and build facilities locally in pivot locations (Exhibit 5.3.1) for 
cultivation in order to be able to more easily export in the region, such as the 
Australian hub for potential Asian markets. The Company has already acquired a 
greenhouse (in Odense, Denmark26) and is planning to begin its first cultivation in 
the beginning of 2019. Other Canadian competitors have also adopted a similar 
strategy, Aurora is expected to complete its facility in Denmark by end 201927, 
Canntrust partnered up with Stenocare, a cannabis producer based in Denmark28 
and Tilray has built a production facility in Portugal29. As concerns local 
                                                 
25 Idem 13 
26 Roth, H. (2018). CannTrust Continues Global Expansion as Danish Partner, STENOCARE, Receives License to Distribute CannTrust Products | CannTrust. [online] 
CannTrust. Available at: https://canntrust.ca/canntrust-continues-global-expansion-as-danish-partner-stenocare-receives-license-to-distribute-canntrust-products/ 
27 Reuters. (2018). Aurora Cannabis teams up with Danish tomato producer to sell pot in.... [online] Available at: https://www.reuters.com/article/aurora-cannabis-
alfredpedersen/aurora-cannabis-teams-up-with-danish-tomato-producer-to-sell-pot-in-europe-idUSL4N1OZ3JS/ 
28 Idem 26 
29 Financial Post. (2018). Tilray to build $30 million EU cannabis production operation in Portugal. [online] Available at: 
https://business.financialpost.com/commodities/agriculture/tilray-to-build-30-million-eu-cannabis-production-operation-in-portugal 
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competitors, they lack a first mover advantage as Canadian players gained 
valuable insight into the cannabis industry and patient preferences when compared 
to their local counterparts and have been investing into infrastructure, research 
and development, expansion and automation of product capacity. Finally, another 
important aspect that is unique to the Company is their strategy to advise and 
educate players in the cannabis industry globally through their educational 
packages such as the one put forward by Spektrum, their German subsidiary.  
At present, based on Health Canada export figures of all the registered Canadian 
LPs, Canopy Growth is the largest exporter of cannabis among its peers. Canopy 
accounted for 46% of all the exports made by Canadian LPs in the first 9 months 
of 2018, reaching 85% of all the exports made in Q2 2019 (Exhibit 5.3.2.). We 
believe that Canopy Growth will continue to be at the forefront of the international 
medical industry having a market share of 11% in 2020 and stabilizing around 7% 
in 2025. In terms of revenues for Canopy Growth, while international revenues had 
previously accounted for less than 3% of the Company’s total medical revenues, 
Given the likelihood of medical legalisation globally, we predict that, by the end of 
2022, international medical cannabis revenues will surpass domestic medical 
sales due to the extensive size of the global market.  
6. Recreational Market 
6.1 Historical and Current Market 
While studies show that cannabis has been cultivated for at least 4000 years 
B.C.30, popular recreational consumption began in the 1960s31. Data from Statictics 
Canada indicates that the annual volume consumption has been consistently 
growing for the last 50 years at a CAGR of 3.9% (Exhibit 6.1.1.), with around 775 
tonnes of cannabis being consumed in 2017 corresponding to an estimated market 
value of C$5.7 billion, based on an average price per gram of C$7.48 and on 
13.18% of the total population having consumed it in the past year thus annually 
spending C$1,200 each32. Since 17 October 2017, the recreational cannabis 
market is open and regulated in Canada under the Cannabis Act. In order to 
operate, LPs must hold a license, issued by Health Canada, certifying their 
compliance under the Cannabis Act. The criteria for granting a license is linked to 
set security standards, facility standards, quality assurance standards and good 
product practices, amongst others. As of August 2018, there are currently 115 LPs 
                                                 
30 Grinspoon, L. (2005). History of Cannabis as a Medicine. 
31 Idem 1 
32 https://www150.statcan.gc.ca/n1/pub/13-610-x/cannabis-eng.htm  
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in Canada which are allowed to sell cannabis33 and as of October 2018, there are 
132 licensed facilities, 69 of them in Ontario, authorised to carry out production. 
Each province of Canada has its own regulatory regime in place to govern the 
supply to consumers. Depending on the province’s framework, LPs may sell to 
government operated establishments and/or private retailers under governmental 
control, who in turn will deliver the product to the general public and/or through 
online sales. In terms of the consumer, the only restriction to purchasing and 
consuming is minimum legal age, which varies from province to province, but which 
tends to mirror the age for alcohol consumption34. However, as legalisation is still 
recent, it may take provinces several months before being fully operational. 
Currently, most of the cannabis sales take place online, with only a few of the 
provinces having put in place the necessary regulatory framework to allow a retail 
store experience. For example, Ontario, accounting for 40% of the total population, 
will only be able to open retail stores in April 2019. Additionally, product choice is 
also limited as under the current legal framework, only dried flower, oil and soft gel 
capsules may presently be sold. Beverages and edibles are predicted to enter the 
market in the course of 2019. 
Internationally, Canada is the second country, after Uruguay, to legalise the 
recreational use of cannabis and the first country of the G20 to do so. In the U.S.A. 
10 states have legalized the recreational sale and consumption of marijuana, with 
Colorado leading the movement in 2012. Other European countries are starting to 
depanelize or are considering full legalisation. However due to the unpredictability 
of the recreational legalisation movement, we will not be considering international 
recreational consumption for the purposes of our report.  
6.2 Potential Market and Development 
CIBC World Markets, the investment banking subsidiary of the Canadian Imperial 
Bank of Commerce, believes that the regulated recreational cannabis market in 
Canada will be worth anywhere from C$5 to C$10 billion per year.35 Similarly, 
Deloitte, a consulting firm, predicts that cannabis sales would reach C$7.17 billion 
in 201936. These estimates coincide with our findings. Given the Health Canada 
data of approximately 775 tonnes in 2017, divided over around 4.8 million 
consumers with an average consumption of 0.44 gram per day and considering 
the historical consumer growth has been rising at CAGR of 3.9% over the past 5 
years (Exhibit 6.2.1.), we expect the CAGR will amount to 5% in 2025. We believe 
                                                 
33 Idem 12 
34 https://www.cbc.ca/news/canada/marijuana-faq-legalization-need-to-know-1.4862207 
35 https://internationalcbc.com/canadian-imperial-bank-of-commerce-expects-cannabis-sales-to-rival-wine/ 
36 2018 Cannabis Report. (2018). Deloitte. 
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that the rate will be climbing at a swifter pace because some potential consumers 
have not able to or did not want to take part in the illicit market. As a result, we 
predict that by the year 2025, 17.50% of Canadians (meaning 6.8 million 
consumers) will have consumed cannabis recreationally at least once in the past 
year compared to 13.18% in 2017. Accordingly, we anticipate that the daily intake 
of cannabis will grow from an average 0.44 grams in 2017 at a CAGR of 2.5% thus 
reaching 0.54 grams per day in 2025 (Exhibit 6.2.2.). This estimation seems 
coherent with data shown in Colorado’s daily consumption, which was at 0.53 
grams per day in 2017 (4 years following legalisation). Our forecast therefore 
accounts for a 22% increase in daily consumption over six years, which is a 
prudent number when compared to Deloitte’s 2018 Cannabis Report, which 
measures it to be at 20% upon legalization37.  
Despite the legalisation of the recreational marijuana market, we believe that this 
increasing demand for cannabis will continue to be supplied in the first few years 
by the illicit market but then gradually retract. We believe the most important factors 
to ensure conversion are accessibility and price of the legal product. The 
government margins (excise tax and sales tax) may affect the competitiveness of 
prices. PBO Legalized Cannabis: Fiscal Considerations’ 2016 report38 indicates 
that if legal prices are equal to illicit price conversion rate will be 98% while at a 
C$1 premium, the rate decreases to 65%. Access to stores will also be limited at 
the beginning thereby some customers will still buy through the illicit market. As 
competition increases and provinces put in place regulatory frameworks to open 
retail stores, we believe the conversation rate will increase year by year until the 
underground market will disappear, according to our calculation by 2020. This is 
further backed by the found in Colorado (U.S.A.), where the illicit market had been 
fully converted into the regulated market in 2017 (after three years of legalisation). 
The speed of the absorption had in fact surpassed expectations, as a study in 2014 
expected that the regulated market would only assimilate 65% of the demand39. 
Considering the transfer rate from legal to illicit, we believe that the total demand 
in kg will grow at a CAGR of 7.6% each year over the forecasted period reaching 
an overall consumption of 1.3 million kg in 2025 (Exhibit 6.2.3) As concerns product 
preferences, we believe recreational demand will likely follow the already existing 
medical preferences and figures observed in Colorado, which means an overall 
predilection for consumption of cannabis as an extract, for example in oil, softgel 
capsules, edibles and beverages as opposed to the dried flower, as consumers 
have been increasingly aware of the negative health effects of traditional smoking. 
                                                 
37 2018 Cannabis Report. (2018). Deloitte. 
38 MARKET SIZE AND DEMAND FOR MARIJUANA IN COLORADO 2017 MARKET UPDATE. (2018). Marijuana Policy Group. 
39Idem 38 
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This claim is further justified by the Colorado example, where since the legalisation 
in 2014, dried flower consumption went down from 66.1% to 54.1% in 201740 
(Exhibit 6.2.4.). 
6.3 Market Share and and Market Players 
LPs can provide recreational cannabis through online websites, retail stores and 
government owned stores through supply agreements. As concerns the private 
retail stores of LPs, these are only permitted in some provinces, depending on the 
regulatory framework applicable. Canopy Growth has currently secured 8 stores in 
Newfound and Labrador, 15 in Manitoba and 5 Saskatchewan and likely soon in 
Alberta. We think Canopy Growth will open more than 120 stores by the end of 
2025 based on the Company’s strategy to expand on store experience in order to 
further connect with customers (for example the expansion of Tweed Stores and 
the acquisition of Tokyo Smoke). Its closest competitors, Aphria and Aurora do not 
intend to have their own retail presence, but will instead partner up with existing 
retail chains: Aurora with Alcanna Inc. and Aphria with Great North Distributors Inc. 
While the partnerships will be able reach most consumers and have a presence 
on the shelves and the tracking inventory, there will not be the same visibility as 
Canopy Growth’s Tweed or Tokyo Smoke, which create a visual brand identity. 
With respect to sale through government established stores, LPs must have 
secured supply agreements with the respective provinces. Canopy Growth has 
obtained the highest number of supply agreements among its peers in terms of 
volume (34% of total supply agreements, amounting to a supply of 70,000 kg per 
year) (Exhibit 6.2.5). Moreover, the Company is the only company to have been 
selected by all the provinces and territories. Aurora has also gained a large chunk 
of the supply agreements, following the acquisition of two competitors which had 
already-established supply agreements. Aphria, the second largest LP in terms of 
production capacity, captured less than half of the number of supply agreements 
obtained by Canopy Growth. This further underlines that the Company is at the 
forefront of supply and is prepared to meet the ever-growing demand.  
Despite the importance of leading production and satisfying demand, it is essential 
to recognise that in the long term, the market will be oversupplied. Thus, big market 
players should be diversified and integrated. As with the tobacco or beverage 
market, branding is a crucial aspect in gaining market dominance but similarly to 
these, promoting, labelling and packaging will be regulated41 under the Proposed 
Approach to the Regulation of Cannabis. For example, there are requirements as 
                                                 
40 Idem 38 
41 PROPOSED APPROACH TO THE REGULATION OF CANNABIS. (2017). Health Canada. 
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to logos, colours and branding, obligatory plain packaging. Furthermore, marketing 
may not promote consumption for psychoactive effects to new consumers, nor be 
directed towards underage consumers and furthermore must contain responsible 
use statements42. It may therefore prove challenging for companies such as  
Canopy Growth to advertise their products and create brand loyalty. However, 
there is a lot of grey area therefore creating customer loyalty and image is up to 
the imagination of the LPs. One way to do so is Canopy Growth’s approach to 
engage to offer diverse products, formats and uses as it is difficult to predict what 
brand will be successful. In practice, Canopy Growth’s brands include (Exhibit 
6.2.6): Spectrum Cannabis (medical market focus), Tweed and Vert (which were 
both aimed at educating the average consumer on the cannabis plant prior to 
legalisation), Hiku brands, including Van der Pop (targeting women), Maitri (sold 
in Quebec), DOJA (aimed at the premium market) as well as Tokyo Smoke (a 
lifestyle brand that currently sells accessories and clothing, which is soon expected 
to sell marijuana) and finally, its affiliated brands, such as Leafs By Snoop (a 
partnership with Snoop Dog), DNA Genetics (award-winning breeding and growing 
strains), Green House Seed Company (leader in cannabis genetics, awarded) and 
Organa Brands (cannabis extraction). Another way to gain popularity among 
consumers is through the store experience which if appreciated, will develop its 
reputation. The Company certainly has the upper hand in terms of branding, 
particularly due to its relationship to its major shareholder, Constellation Brands 
which has in-depth knowledge of marketing strategies and techniques on large 
scale. Together they are currently developing into the cannabis-based beverage 
market to prepare for 2019 market opening. The Company is therefore aiming to 
create its value-added products rather than concentrate on supply cannabis to 
larger retail companies. Additionally, it is likely that the customer opinion will shift 
towards third-party review websites such as Lift.co, a cannabis strains review 
website. Canopy Growth has already more reviews than its two closest competitors 
together thereby underlining its wide reach (Exhibit 6.2.7). Based on the above 
figures and arguments, we believe that Canopy Growth will gain and maintain a 
20% market share of the total legal recreational market in the first years following 
legalisation but which will then lower to 20% in 2025 due to the oversupply of 
product and higher competition between players. Given our projections of 120 
retail stores by 2025 and sizing averaging 2,000 sqf, we expect the Company to 
generate an annual revenue of C$1.350 per sqf (C$2.7 million per store) (Exhibit 
6.2.8) We have calculated these figures by comparison to a cannabis retail 
company based in the US, MedMen Enterprises Inc., which generates a staggering 
                                                 
42 Lbbonline.com. (2017). Guidelines for Responsible Cannabis Branding and Marketing in Canada. [online] Available at: https://lbbonline.com/news/guidelines-for-
responsible-cannabis-branding-and-marketing-in-canada-released/ 
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US$6.541 per sqf (Q2 2018) but in taking a conservative approach, we believe 
these numbers will be lower for Canada. Our estimates for Canopy Growth’s total 
recreational revenues will reach C$ 1.86 billion in 2025 and with retail revenues 
accounting for 17% (Exhibit 6.2.9). 
7. Financial Analysis 
7.1 Cost of Goods Sold 
Historically, costs of goods sold (“COGS”) were made up of three distinctive 
elements: cost per gram to harvest (labor, utilities such as hydro and water, grow 
nutrients, rent, and allocated overheads), post-harvest cost per gram (costs related 
to the production of value-added products including cannabis oils and soft gel 
capsules) and cost per gram for shipping and fulfillment (pre-packaging and 
dispensing and order fulfilment and shipping along witch package materials such 
as bottles, boxes, and labels). Management decided to stop reporting this metric 
of average cost per gram in Q3 2018, because of its irrelevancy for the future costs 
of the industry. However, in that last reported quarter cost per gram to harvest was 
C$0.59 and the post-harvest cost per gram was C$0.44 per gram, while the most 
significant cost was the shipping and fulfillment which was C$1.50 which included 
the branding and the packaging (Exhibit 7.1.1). Comparing historical average cost 
per gram of each LP is irrelevant, as each of them has different ways to publish 
them, some of them include different costs, and for the purpose of our valuation 
we believe that with new product formats entering the market estimating an 
average cost per gram as COGS is not representative. We believe that the COGS 
will be close to the one we can see in proxy industries such as the tobacco, alcohol 
and pharmaceutical. Gross margins of these industries vary between 50% and 
70%, therefore we assume a gross margin of 60% for Canopy Growth.  
7.2 Operating Expenses 
▪ General & Administrative and Sales & Marketing 
General and administrative (“G&A”) and sales and marketing (“S&M”, together 
“SG&M”) costs have been rising consistently over recent years as these expenses 
reflect the growth stage of the industry. Thus over the last few years the hike in 
costs echo the opening of the recreational market and the connected rise in 
demand. SG&M expenses substantially exceed the total revenues gained over the 
last 3 years. Canopy Growth’s SG&M costs in Q2 2019 account for 326.6% of their 
revenues, while for Aurora and Aphria it accounts for 220.1% and 102.3% 
respectively (Exhibit 7.2.1). More specifically, cannabis companies have been 
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mostly spending in marketing and promotion (20% of expenses), office and facility 
costs (29% of expenses) and consultancy, legal and professional fees (32% of 
expenses). For Canopy Growth, the Company has been incurring considerable 
expenses to expand their facilities and product capacities and to reinforce its 
number of employees (from 100 employess in Q1 2016 to 2000 in Q2 2019) 
(Exhibit 7.2.2) in order to prepare to meet the recreational demand of cannabis 
prior to legalisation. However, we forsee a shift in expenditures, from investing into 
supply capacities and the set up on the market towards a fully fleshed growth 
development. Therefore, in Q2 2019, we believe that 15% of SG&M expenses are 
directly linked to sales volume and 68% are related to business expansions. Once 
companies reach a more mature stage and the supply chain is firmly established, 
we think that SG&M expenses will be considerably lower in terms of the percentage 
of sales (as compared to those prior to development). We expect that these will 
also closely resemble the beverage and tabbaco industry as well as the 
pharmaceutical companies. When averaging the SG&M costs of major players 
within these industries, we obtain a number representing around 24-28% of 
sales.Therefore, Canopy Growth’s SG&M costs will steadily grow over the next 
few years, at a slower rate than previously, until stabilising to reach an approximate 
25% of sales. These costs can be traced to the opening of new recreational retail 
locations throughout Canada, given that the Company intends to open 120 new 
stores by the end of 2025.  
▪ Research and Development 
Canopy Growth’s R&D costs have been increasing quarter over quarter, 
representing on average 2% of revenues (which were prior to legalisation, made 
up purely of medical sales), except for Q2 2019, where expenses reached a high 
of 8% of the revenues. (Exhibit 7.2.4) Canopy Growth is the second biggest 
company by share of R&D expenditures lagging only behing Aurora, which 
currently has 40 clinical trials, in areas such as cancer, pain management, 
osteoarthritis, epilepsy and chronic pain. Additionally, we were not able to find any 
mention of clinical trials from Aphria through their report and presentations to 
investors. (Exhibit 7.2.5) Investing in R&D is crucial for companies to gain a 
significant competitive advantage over other peers by creating added value for 
patients, particularly through the design of specificalised medicine targeting 
specific symptoms. Included in the R&D costs are patent applications and human 
and animal clinical trials which will likely continue to progress, especially following 
the acquisiton of Ebbu, a Colorado based hemp research company. At the 
moment, Canopy Growth has, through its subsidiary, CHI, applied for 39 patents, 
15 human clincal trials and 4 animal health clinical trials. Therefore we anticipate 
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that R&D costs will rise and reach an estimated percentage of 15% of medical 
sales by 2025 (Exhibit 7.2.5). These are coherent with the R&D expenses of 
leading pharmaceutical companies such as Pfizer, Merck & Co and 
GlaxoSmithKline which represent around 15-20% of their sales. 
▪ Operating Profit 
Presently, Canopy Growth has a total accumulated non-capital loss of C$421 
million (including non-capital losses absorbed from the companies it acquired). 
These losses are available in tax credits and we expect the Company to benefit 
from them from Q4 2019 until the end of 2020. The Company’s deferred tax profile 
mainly consists of liabilities arising from temporary differences in the tax base and 
carrying value of assets acquired in M&A deals, as well as liabilities arising from 
fair value changes in the biological assets. Overall, we project the EBITA margin 
to reach 34.6% in 2025, which is above the historical EBITA margin of the 
beverage industry (23.4%) and that of the pharmaceutical industry (23.6%), while 
slightly below that of the tobacco industry (40.6%)43. The difference between the 
first two peer industries arises from fundamental differences in the gross margins. 
Concerning the latter, we believe the cost structure of producing cannabis closely 
resembles that of tobacco, which has a historical gross margin of 60%44. However, 
this figure is slightly tweaked due to the considerable excise tax on tobacco (which 
can vary between 40-70% depending on the region45), while the expected excise 
tax on cannabis products in Canada varies between 5 and 13% depending on the 
province46.  
7.3 Invested Capital 
▪ Working Capital 
In the last fiscal quarter, Canopy Growth reported an operating cycle of 1240 days 
and a cash conversion cycle of 374. These figures reflect the amount of inventory 
the Company ramped up to prepare itself for the opening of the recreational 
market. We estimate, in correlation with the proxy industries, that the days 
collection period will trend towards 47 days, while the amount of days payable will 
incline towards 60 days. In one year, the cannabis plant can produce 3 to 4 
harvests, which corresponds to a period of 90 to 120 days. Thus, we project the 
days inventory outstanding to be 150 days. Overall, we expect Canopy Growth will 
                                                 
43 Damodaran, A. (2018). Operating and Net Margins. [online] Available at: http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/margin.html 
44 Idem 43 
45 Global and regional overview of cigarette prices and taxation. (n.d.). World Health Organization. 
46 Excise duty framework for cannabis. [online] Canada.ca. Available at: https://www.canada.ca/en/revenue-agency/campaigns/cannabis-taxation.html 
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have an operating cycle of 197 days and a cash conversion cycle of 137 days by 
2025. (Exhibit 7.3.1) 
▪ Capital Expenditures 
We broke down Canopy Growth’s invested capital into several different 
compartments: working capital (covered in point 7.3), property, goodwill, intangible 
assets, plant and equipment (“PPE”) and other assets. Companies in the industry 
have been racing to conquer market share, by absorbing smaller players at 
expeditious rate, often paying sizeable amounts for them. There are three 
fundamental reasons for this: absorb production capacity faster (rather than having 
to build production facilities from scratch), absorb companies with already 
established specialised technology and intellectual property and tap into the 
international markets by acquiring companies which are already licensed in these 
countries. These various acquisitions have led to a strong goodwill on their balance 
sheet, with Canopy Growth reporting it to be 55% of its invested capital, whilst 
Aphria reported 36% and Aurora 64%. Some analysts believe that cannabis 
companies may be overpaying for their acquisitions. We think this concern to be 
more suitable for a case by case analysis. Overall it has been essential for 
companies to obtain critical resources, allowing them to fuel growth under a 
sustained return on invested capital and gain a competitive advantage over their 
peers.  
As of the last fiscal quarter, Canopy has C$103,867 in intangible assets, 
representing 5% of its invested capital. Health Canada licenses represent 59% of 
the Company’s intangible assets, while distribution channels represent 25% and 
brands represent 6%. We believe the overall relative weight of intangible assets is 
poised to grow all the way to 28% of its invested capital in 2025 (Exhibit 7.3.2), 
mainly via patents and licenses. Canopy Growth’s PPE currently stands at 33% of 
the invested capital and represents a capacity of production of 60,868 kg of 
cannabis. However, only 50% of the PPE is responsible for its production capacity. 
47% represent on-going projects and 3% reflect administrative purposes. The 
management, in particular Bruce Linton, has clearly stated that the upcoming two 
years are crucial for cannabis companies to obtain a dominant position on the 
market. Another way to do so is to deploy large cash reserves as this allows the 
Company to be flexible on the market and act faster than its competitors if a new 
international medical market opens up. Based on this, we forecast Canopy Growth 
deploying C$1 billion in 2019, C$1.1 billion in 2020 and C$950 million in 2021. 
Moreover, we predict that the Company will deploy the remaining of Constellation 
Brands’s cash injection at decreasing rates until 2025, with a cash deployment of 
C$350 million in the last year. 
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8. Valuation 
8.1 Cost of Capital 
To discount the Company’s cash flows, we have determined a 2-stage weighted 
average cost of capital (“WACC”) solution to account for any possible changes in 
the capital structure. Canopy Growth’s current capital structure is far from efficient, 
as the company, along with its peers, have mainly used equity issuance to fund 
their growth. Currently, the Company’s debt consists of convertible senior notes 
for the principal amount of C$600 million and other small loans. Nonetheless, with 
the ability of the Company to invest in capital expenditure without the need for 
further external funding, we think that the Company will not have a need to rely on 
debt instruments for years to come. We have thus discounted the company’s cash 
flows with the current WACC until 2030 (the year we project that the Company will 
be in a steady state) and we have discounted the terminal value cash flows with 
the target WACC. To determine the WACC for each stage, we have used the 
following inputs: a cost of debt of 3.89%, based on the weighted average yield to 
maturity (“YTM”) of 10-year bonds outstanding for companies in the beverage, 
tobacco and pharmaceutical industry; a cost of equity under the capital asset 
pricing model (“CAPM”); a risk-free rate of 2.48% based on a 10-year Canadian 
government bond; a risk premium of 5% according to Damodaran; a bottom-up 
beta; a tax rate of 26.5% and a current debt to equity, target debt to equity. In order 
to calculate the bottom-up beta, we used the average unlevered beta for the 
beverage, tobacco and pharmaceutical industry according to Damodaran, 
calculated the weighted average unlevered beta using the weights of Canopy 
Growth’s revenues in 2025, and then releveled the beta with the Company’s capital 
structure. For the initial stage, we based ourselves on a debt to equity of 8.78%, 
which corresponds to the Company’s current capital structure, arriving to a beta of 
1.00, a cost of equity of 7.47% and WACC of 7.10%; while for the steady stage, 
we applied the weighted average debt to equity of the proxy industries of 18.06%, 
arriving to a beta of 1.06, a cost of equity of 7.81% and a WACC of 7.03%. 
8.2 Discounted Cash Flows 
To discount the company’s cash flows we applied a 3-stage discounted cash flow 
model (“DCF”) with the following phases: a 1st stage consisting of the explicit 
forecasted cash flows until 2025 and a 2nd stage containing the cash flows 
projected until 2030 where the return on new invested capital (“RONIC”) and 
investment rate (“IR”) trend towards the steady state of 22% and 15%, respectively. 
We project the steady state RONIC at 22% by using the weighted average RONIC 
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of the beverage and pharmaceutical industry. We discarded the RONIC figure for 
the tobacco industry due to the idiosyncrasies that the industry is facing in terms 
of high taxes and the general effort of governments to crack down on consumption 
which has resulted in an industry that is divesting at a rate of 17%. Based on the 
steady state of ROIC and of IR, we have determined the nominal terminal growth 
rate to be at 3.30%. We can break down this figure into an expected long-term 
inflation rate of 2.08% and a real terminal growth rate of 1.2%. Our model discloses 
a buy recommendation for Canopy Growth at a Y 2019 share price of C$46.90 (an 
annual return of 19.4% considering its current share price of C$39.28). We 
therefore conclude an enterprise value of C$16.283 billion and after having 
subtracted the minority interest of C$ 209 million, we calculate the equity value to 
be at C$ 16.074 million.  
8.3 Scenario Analysis 
Bearing in mind the difficulty and uncertainty of this new industry, we have 
disentangled our valuation into four possible scenarios: two scenarios in which the 
international and recreational sales outperform or underperform and a bull or bear 
scenario where we revise prices and gross margin up or down. These scenarios 
are meant to account for positive or negative factors that could affect Canopy 
Growth valuation. In terms of upsides, it is possible that small competitors will not 
be able to sustain their market share due to a lack of economics of scale thereby 
advantaging bigger players; value added products (oils, beverages, edibles etc.) 
will greatly increase revenues; the Company will be more efficient in resource 
allocation;  the arrival of added value products increasing prices of oils, beverages 
and edibles; demand surpasses expectation, international regulatory changes are 
quicker than expected as other countries can use the Canadian template to model 
their framework. In the optimistic scenario, we project the penetration rate of the 
international market to be 1.25% as opposed to 1%, whereas in the pessimistic 
scenario we project the rate to be 0.75%. We also project a steady state market 
share in the recreational market of 25% and 15%, as opposed to the 15% in our 
base case. In the bull/bear scenario, we trend the final retail oil price per gram to 
be at C$ 21.2 and C$ 8.7, respectively, as opposed to C$ 14.9 in our base case. 
We also stretch the company’s gross margin from 65-55%, respectively, compared 
to the base case margin of 60%. 
8.4 Sensitivity Analysis 
In this section, we run a sensitivity analysis on two main inputs of our valuation: 
terminal growth rate; terminal WACC. It is important to bear in mind the uncertainty 
Scenarios 
Target 
Price 
Probability 
Bullish Scenario 82,62 6% 
Optimist Scenario 57,14 47% 
Pessimist Scenario 36,82 27% 
Bearish Scenario 25,18 20% 
Expected Scenario 46,90 46,90 
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involved in these two inputs, taking into account the early bird stage of the industry. 
Concerning the WACC calculation, we have decided to calculate the ordinary least  
squares (OLS) beta using 8 Canadian cannabis companies and arrived to an  
average OLS beta of 0.92. However, we decided to stick with the bottom-up beta 
, given the unreasonable volatility observed in the OLS beta confidence interval [-
0.84;2.69]. We have decided the WACC to vary between 6-8% and the growth rate  
to vary between 2-4%, which we find to them be a range of reasonable variance. 
As we can see from the Exhibit 8.4, the price target is very sensitive to these inputs 
and it varies from $C30-75 within our sensitivity analysis. However, in most of the 
inputs values the stock remains a buy recommendation. 
9. Risk Factors 
The future size of the global cannabis market is highly uncertain and depends on 
the regulatory environment in many countries. Canopy Growth’s internal forecasts, 
as well as our own, are highly dependent on predicting a number of uncertain 
events, including government policy and changes in consumer trends. Thus, 
Canopy Growth may misallocate resources which might jeopardize its profits. The 
Company faces a high degree of execution risk in ramping up production, such as 
delays, quality issues and further costs. These in turn can lead to product recalls 
and erode profit. Future over supply in the market due to intensive competition may 
lead to significant pricing pressure in the market, reducing profitability. Moreover, 
there is still no guarantee that its brands will be winners. The Company may 
struggle to integrate acquired companies in the overall organization or paying more 
than it should for its acquisitions. As the Company expands internationally, foreign 
exchange fluctuations can erode the Company’s profits oversees. Canopy 
Growth’s share price has experienced significant volatility and is likely to be subject 
to it in the future as a result of market events. Our forecasts and target price 
estimate are opinions based on our fundamental analysis of the industry and the 
Company, therefore they should not be taken as factual. 
 
 
 
 
  
WACC 
 46,90 6,00% 6,50% 7,00% 7,50% 8,00% 
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2,00% 44 39 35 32 30 
2,50% 49 43 38 34 32 
3,00% 54 47 41 37 33 
3,50% 63 53 45 40 36 
4,00% 75 60 51 44 39 
Exhibit 8.4 – Sensitivity analysis 
Source: Analyst estimates 
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Appendix 
Financial Statements 
Forecasting Income Statement          
Income Statement 2018 2019 2020 2021 2022 2023 2024 2025 
Revenues 77,948 308,910 894,256 1,307,212 1,774,720 1,987,438 2,297,780 2,827,763 
Growth in % 95.4% 296.3% 189.5% 46.2% 35.8% 12.0% 15.6% 23.1% 
Cost of Good Sold -37,790 -147,547 -357,703 -522,885 -709,888 -794,975 -919,112 -1,131,105 
Non-Cash Inventory Items 34,034 -9,651 0 0 0 0 0 0 
Gross profit  74,192 151,711 536,554 784,327 1,064,832 1,192,463 1,378,668 1,696,658 
Gross Margin % 95.2% 49.1% 60.0% 60.0% 60.0% 60.0% 60.0% 60.0% 
Sales and Marketing -38,203 -98,038 -149,043 -213,511 -283,955 -311,365 -352,326 -424,164 
% of revenue 49.0% 31.7% 16.7% 16.3% 16.0% 15.7% 15.3% 15.0% 
General and administration  -43,819 -98,414 -141,591 -191,724 -239,587 -245,117 -256,585 -282,776 
% of revenue 56.2% 31.9% 15.8% 14.7% 13.5% 12.3% 11.2% 10.0% 
Research and development -1,453 -9,232 -6,387 -11,312 -19,840 -36,099 -69,744 -145,571 
% of revenue 1.9% 3.0% 0.7% 0.9% 1.1% 1.8% 3.0% 5.1% 
Acquisition costs -3,406 -10,086 -11,000 -9,500 -8,000 -6,500 -5,000 -3,500 
Share based compensation (Non-Cash) -49,106 -125,922 0 0 0 0 0 0 
EBITDA -61,795 -189,981 228,534 358,280 513,450 593,381 695,012 840,646 
% of revenue -79.3% -61.5% 25.6% 27.4% 28.9% 29.9% 30.2% 29.7% 
Depreciation of PPE -8,725 -23,907 -34,299 -48,496 -60,780 -71,529 -80,366 -86,916 
Average Life 23.7 25 24 24 24 23 23 23 
EBITA (Recurring) -70,520 -213,888 194,234 309,783 452,670 521,852 614,646 753,730 
% of revenue -90.5% -69.2% 21.7% 23.7% 25.5% 26.3% 26.7% 26.7% 
Non-Recurring Operating Items -19,723 0 0 0 0 0 0 0 
% of revenue -25.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 
EBITA (with Non-Recurring Items) -90,243 -213,888 194,234 309,783 452,670 521,852 614,646 753,730 
% of revenue -115.8% -69.2% 21.7% 23.7% 25.5% 26.3% 26.7% 26.7% 
Operating Cash Tax Recovery (Expense) -9,935 0 0 0 0 -82,717 -119,388 -164,950 
% of EBITA 14.1% 0.0% 0.0% 0.0% 0.0% -15.9% -19.4% -21.9% 
NOPLAT -100,178 -213,888 194,234 309,783 452,670 439,135 495,258 588,781 
% of revenue -128.5% -69.2% 21.7% 23.7% 25.5% 22.1% 21.6% 20.8% 
Non Operating Items 36,735 -201,249 0 0 0 0 0 0 
Net Income (Adjusted) -63,443 -415,137 194,234 309,783 452,670 439,135 495,258 588,781 
% of revenue -81.4% -134.4% 21.7% 23.7% 25.5% 22.1% 21.6% 20.8% 
 
Forecasting Balance Sheet          
CAD 000's 2018 2019 2020 2021 2022 2023 2024 2025 
Working cash 3,897 15,445 44,713 65,361 88,736 99,372 114,889 141,388 
Accounts receivable 21,425 40,426 102,512 147,492 200,315 231,818 282,496 376,239 
Inventory & Biological Assets 117,955 106,079 147,001 214,884 291,735 326,702 377,717 464,838 
Current Operating Assets 143,277 161,950 294,225 427,737 580,786 657,892 775,102 982,465 
Operating cycle 1240 310 192 191 191 193 195 199 
Current Operating Liabilities 70,634 44,140 40,915 59,809 81,200 90,932 105,131 129,380 
Net Working Capital 72,643 117,810 253,310 367,927 499,586 566,960 669,971 853,085 
Cash conversion cycle 374 175 132 131 131 133 135 139 
Property, plant and equipment  303,682 638,808 1,003,809 1,300,162 1,557,183 1,766,129 1,918,638 2,006,722 
% of Total Funds 21.9% 8.7% 12.7% 15.7% 17.7% 19.0% 19.5% 19.2% 
Intangible assets 144,501 485,422 884,722 1,229,572 1,547,372 1,827,847 2,060,722 2,235,722 
% of Total Funds 10.4% 6.6% 11.2% 14.8% 17.5% 19.6% 20.9% 21.3% 
Goodwill 314,923 1,251,158 1,552,558 1,812,858 1,977,258 2,066,308 2,100,558 2,100,558 
% of Total Funds 22.7% 17.1% 19.7% 21.9% 22.4% 22.2% 21.3% 20.0% 
Other long-term assets 8,340 26,776 26,776 26,776 26,776 26,776 26,776 26,776 
Invested Capital 844,089 2,519,975 3,721,175 4,737,296 5,608,175 6,254,020 6,776,665 7,222,863 
Excess Cash 318,663 4,425,263 3,795,579 3,181,373 2,844,055 2,692,919 2,709,025 2,886,397 
% of Total Funds 22.9% 60.5% 48.1% 38.4% 32.2% 28.9% 27.5% 27.6% 
Financial Assets 226,569 367,390 367,390 367,390 367,390 367,390 367,390 367,390 
% of Total Funds 16.3% 5.0% 4.7% 4.4% 4.2% 3.9% 3.7% 3.5% 
Total Funds Invested 1,389,321 7,312,629 7,884,144 8,286,059 8,819,620 9,314,329 9,853,080 10,476,650 
Total Debt 69,572 7,750 7,750 7,750 7,750 7,750 7,750 7,750 
Total Equity 1,319,749 7,304,879 7,876,394 8,278,309 8,811,870 9,306,579 9,845,330 10,468,900 
 
Free Cash Flow             
CAD 000's 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 
NOPLAT -8,194 5,028 16,362 -100,178 -213,888 194,234 309,783 452,670 439,135 495,258 588,781 
Gross Cash Flow -5,001 10,785 30,551 -40,276 -64,059 228,534 358,280 513,450 510,664 575,624 675,697 
Gross Investment -21,035 -110,509 -475,631 -250,711 -1,701,193 -1,235,500 -1,064,617 -931,659 -717,374 -603,010 -533,115 
Free Cash Flow -26,036 -99,724 -445,080 -290,987 -1,765,252 -1,006,966 -706,338 -418,209 -206,710 -27,387 142,582 
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International Market Forecast (2025) 
 
 
 
 
 
 
 
 
Disclosures and Disclaimers 
Report  Recommendations 
Buy Expected total return (including expected capital gains and expected dividend yield) 
of more than 10% over a 12-month period. 
Hold Expected total return (including expected capital gains and expected dividend yield) 
between 0% and 10% over a 12-month period. 
Sell Expected negative total return (including expected capital gains and expected 
dividend yield) over a 12-month period. 
 
This report was prepared by [insert student’s name], a Master in Finance student of Nova School of Business 
and Economics (“Nova SBE”), within the context of the Field Lab – Equity Research. 
This report is issued and published exclusively for academic purposes, namely for academic evaluation and 
master graduation purposes, within the context of said Field Lab – Equity Research. It is not to be construed 
as an offer or a solicitation of an offer to buy or sell any security or financial instrument. 
This report was supervised by a Nova SBE faculty member, acting merely in an academic capacity, who revised 
the valuation methodology and the financial model. 
Given the exclusive academic purpose of the reports produced by Nova SBE students, it is Nova SBE 
understanding that Nova SBE, the author, the present report and its publishing, are excluded from the persons 
and activities requiring previous registration from local regulatory authorities. As such, Nova SBE, its faculty 
and the author of this report have not sought or obtained registration with or certification as financial analyst by 
any local regulator, in any jurisdiction. In Portugal, neither the author of this report nor his/her academic 
supervisor is registered with or qualified under COMISSÃO DO MERCADO DE VALORES MOBILIÁRIOS (“CMVM”, the 
Country 2025 Population 2017 GDP (Trillion $US) GDP per Capita 
Projected Annual 
Consumer Spending (USD) 
Potential Market Value ($US Billion) Canopy Rank Canopy Share ($US millions) 
Germany 82,455                                 3.68                              44,599  1642                                            1,354                                            1                                                                     162  
Brazil 220,371                                 2.06                                 9,327  343                                               757                                            2                                                                       38  
Italy 58,623                                 1.93                              33,004  1215                                               712                                            2                                                                       36  
Canada 39,173                                 1.65                              42,199  1554                                                  -                                              1                                                                        -    
Australia 26,857                                 1.32                              49,276  1814                                               487                                            1                                                                       58  
Mexico 141,132                                 1.15                                 8,148  300                                               423                                            2                                                                       21  
Turkey 86,125                                 0.85                                 9,882  364                                               313                                            3                                                                        -    
Netherlands 17,414                                 0.83                              47,444  1747                                               304                                            3                                                                        -    
Switzerland 8,955                                 0.68                              75,815  2791                                               250                                            2                                                                       12  
Argentina 47,480                                 0.64                              13,429  494                                               235                                            2                                                                       12  
Poland 37,373                                 0.52                              14,034  517                                               193                                            2                                                                       10  
Israel 9,349                                 0.35                              37,528  1382                                               129                                            3                                                                        -    
Colombia 51,854                                 0.31                                 5,963  220                                               114                                            1                                                                       14  
Chile 10,945                                 0.28                              25,316  932                                               102                                            1                                                                       12  
Peru 35,131                                 0.21                                 6,017  222                                                 78                                            2                                                                          4  
Czech Republic 10,613                                 0.22                              20,327  748                                                 79                                            1                                                                       10  
Greece 10,945                                 0.20                              18,300  674                                                 74                                            2                                                                          4  
Uruguay 10,945                                 0.06                                 5,131  189                                                 21                                            2                                                                          1  
Croatia 4,003                                 0.05                              13,702  504                                                 20                                            2                                                                          1  
Jamaica 2,934                                 0.01                                 5,033  185                                                   5                                            1                                                                          1  
Macedonia, FYR 2,088                                 0.01                                 5,429  200                                                   4                                            2                                                                          0  
Lesotho 2,466                                 0.00                                 1,070  39                                                   1                                            1                                                                          0  
United Kingdom 69,074                                 2.62                              37,966  1398                                               965                                            1                                                                     116  
Denmark 5,913                                 0.32                         54,941.20  2023                                               120                                            1                                                                       14  
Thailand 69,685                                 0.46                           6,532.51  241                                               168                                            3                                                                        -    
India 1,451,829                                 2.60                           1,789.12  66                                               956                                            3                                                                        -    
France 66,842                                 2.58                         38,635.94  1422                                               951                                            2                                                                       48  
Spain 46,307                                 1.31                         28,318.08  1043                                               483                                            1                                                                       58  
Sweden 10,435                                 0.54                         51,559.45  1898                                               198                                            2                                                                       10  
South Africa 61,790                                 0.35                           5,654.95  208                                               129                                            3                                                                        -    
Portugal 10,048                                       0                         21,653.59  797        80                                           2                                                                          4  
    Total Market (USD)                                            9,706                                                                       645  
    Total market (CAD)                                         12,564                                                                       835  
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Portuguese Securities Market Authority) as a financial analyst. No approval for publication or distribution of this 
report was required and/or obtained from any local authority, given the exclusive academic nature of the report. 
The additional disclaimers also apply: 
USA: Pursuant to Section 202 (a) (11) of the Investment Advisers Act of 1940, neither Nova SBE nor the author 
of this report are to be qualified as an investment adviser and, thus, registration with the Securities and 
Exchange Commission (“SEC”, United States of America’s securities market authority) is not necessary. 
Neither the author nor Nova SBE receive any compensation of any kind for the preparation of the reports. 
Germany: Pursuant to §34c of the WpHG (Wertpapierhandelsgesetz, i.e., the German Securities Trading Act), 
this entity is not required to register with or otherwise notify the Bundesanstalt für Finanzdienstleistungsaufsicht 
(“BaFin”, the German Federal Financial Supervisory Authority). It should be noted that Nova SBE is a fully-
owned state university and there is no relation between the student’s equity reports and any fund raising 
programme. 
UK: Pursuant to section 22 of the Financial Services and Markets Act 2000 (the “FSMA”), for an activity to be 
a regulated activity, it must be carried on “by way of business”. All regulated activities are subject to prior 
authorization by the Financial Conduct Authority (“FCA”). However, this report serves an exclusively academic 
purpose and, as such, was not prepared by way of business. The author - a Master’s student - is the sole and 
exclusive responsible for the information, estimates and forecasts contained herein, and for the opinions 
expressed, which exclusively reflect his/her own judgment at the date of the report. Nova SBE and its faculty 
have no single and formal position in relation to the most appropriate valuation method, estimates or projections 
used in the report and may not be held liable by the author’s choice of the latter. 
The information contained in this report was compiled by students from public sources believed to be reliable, 
but Nova SBE, its faculty, or the students make no representation that it is accurate or complete, and accept 
no liability whatsoever for any direct or indirect loss resulting from the use of this report or of its content. 
Students are free to choose the target companies of the reports. Therefore, Nova SBE may start covering 
and/or suspend the coverage of any listed company, at any time, without prior notice. The students or Nova 
SBE are not responsible for updating this report, and the opinions and recommendations expressed herein may 
change without further notice. 
The target company or security of this report may be simultaneously covered by more than one student. 
Because each student is free to choose the valuation method, and make his/her own assumptions and 
estimates, the resulting projections, price target and recommendations may differ widely, even when referring 
to the same security. Moreover, changing market conditions and/or changing subjective opinions may lead to 
significantly different valuation results. Other students’ opinions, estimates and recommendations, as well as 
the advisor and other faculty members’ opinions may be inconsistent with the views expressed in this report. 
Any recipient of this report should understand that statements regarding future prospects and performance are, 
by nature, subjective, and may be fallible. 
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This report does not necessarily mention and/or analyze all possible risks arising from the investment in the 
target company and/or security, namely the possible exchange rate risk resulting from the security being 
denominated in a currency either than the investor’s currency, among many other risks. 
The purpose of publishing this report is merely academic and it is not intended for distribution among private 
investors. The information and opinions expressed in this report are not intended to be available to any person 
other than Portuguese natural or legal persons or persons domiciled in Portugal. While preparing this report, 
students did not have in consideration the specific investment objectives, financial situation or particular needs 
of any specific person. Investors should seek financial advice regarding the appropriateness of investing in any 
security, namely in the security covered by this report. 
The author hereby certifies that the views expressed in this report accurately reflect his/her personal opinion 
about the target company and its securities. He/ She has not received or been promised any direct or indirect 
compensation for expressing the opinions or recommendation included in this report. 
[If applicable, it shall be added: “While preparing the report, the author may have performed an internship 
(remunerated or not) in [insert the Company’s name]. This Company may have or have had an interest in the 
covered company or security” and/ or “A draft of the reports have been shown to the covered company’s officials 
(Investors Relations Officer or other), mainly for the purpose of correcting inaccuracies, and later modified, prior 
to its publication.”]  
The content of each report has been shown or made public to restricted parties prior to its publication in Nova 
SBE’s website or in Bloomberg Professional, for academic purposes such as its distribution among faculty 
members for students’ academic evaluation. 
Nova SBE is a state-owned university, mainly financed by state subsidies, students tuition fees and companies, 
through donations, or indirectly by hiring educational programs, among other possibilities. Thus, Nova SBE 
may have received compensation from the target company during the last 12 months, related to its fundraising 
programs, or indirectly through the sale of educational, consulting or research services. Nevertheless, no 
compensation eventually received by Nova SBE is in any way related to or dependent on the opinions 
expressed in this report. The Nova School of Business and Economics does not deal for or otherwise offer any 
investment or intermediation services to market counterparties, private or intermediate customers. 
This report may not be reproduced, distributed or published, in whole or in part, without the explicit previous 
consent of its author, unless when used by Nova SBE for academic purposes only. At any time, Nova SBE may 
decide to suspend this report reproduction or distribution without further notice. Neither this document nor any 
copy of it may be taken, transmitted or distributed, directly or indirectly, in any country either than Portugal or 
to any resident outside this country. The dissemination of this document other than in Portugal or to Portuguese 
citizens is therefore prohibited and unlawful. 
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Cannabis Infused Beverages Could Drive the Next Big Wave of Demand  
On 17 October 2018, Canada became the first G7 country and the second in the world (after 
Uruguay) to legalise the consumption of cannabis for recreational purposes. A first wave 
legalised the sale of dried flower, oil and softgel capsules but a second is to follow in the course 
of 2019, for the legalisation of edibles, concentrates and infused beverages. These products will 
allow companies to more clearly differentiate themselves from competitors and create branded 
value-added products targeted at current but also completely new demographics of consumers. 
Our focus in this report will be to establish how and why cannabis infused beverages could 
disrupt incumbent sectors such as the alcohol industry ($US 837 billion in 20171) and more 
specifically, the beer industry which was valued at $USD 281 billion in 20172. Important actors 
of the beverage industry have already begun projecting strategies while others are silently 
observing the development of this nascent industry.  
• Historical and Current Beer Market 
The cannabis sector has become of high interest for big players in the beverage industry since 
beer consumption has been declining over the past decade. In Canada, beer sales have been 
constantly decreasing from 22.97 million hectoliters in 2012 to 22.18 million hectoliters in 
20173, at a CAGR of -0.70%, while population growth increased at a CAGR of 1.10% over the 
same period.4 Similarly, the soft drink consumption per capita in Canada has been seriously 
decreasing from 104 liters in 2005 to 65 liters in 2018 at a CAGR of -3.6%5. This decline is 
linked to the health concerns of high sugar content, and while originally, diet or light versions 
recovered the demand, consumers have now began shifting away from artificial sweeteners. 
                                                             
1 https://www.statista.com/forecasts/758153/revenue-of-the-alcoholic-drinks-market-worldwide-by-country 
2 https://www.statista.com/forecasts/758148/revenue-of-the-beer-market-worldwide-by-country 
3 https://www.statista.com/statistics/331951/beer-sales-in-canada/ 
4 https://www.stats.gov.nl.ca/statistics/population/pdf/annual_pop_prov.pdf 
5 https://www.statista.com/statistics/452971/soft-drink-consumption-per-capita-in-canada/ 
Therefore, soft drink manufactures can also benefit from cannabis-infused product 
development. In comparison with the drops in the demand for these industries, cannabis 
consumption in the form of dried flower has increasing between 2012 and 2017 at a CAGR of 
4.0%, reaching a total volume of 773.4 tonnes6. 
Individuals surveyed in a study in Canada in 2017, say they choose to consume healthy food 
and beverages to ensure their future good health (73%), enhance their daily health (60%) and 
lose weight (43%). Another study indicates that 57% of US beer drinkers favour light beer7. 
Light beer was invented by the biochemist James Owandes in order to obtain a lower calorie 
product with an average of 4.6% alcohol by volume. These examples further emphasise the 
popular trend of healthier eating and drinking. 
• Prohibition Impact 
The alcohol prohibition period has helped society better understand the relationship between 
consumption and prohibition of the substance, the most pertinent of which is that of Richard 
Cowan, named the “Iron Law of Prohibition” 8. This rule states that increased law enforcement 
results in higher potency of the illegal substance. Due to the increased risk of the illicit market, 
the product is likely to be more potent and there is a higher chance that it may be mixed with 
more dangerous substances. This has been the case for the cannabinoid, tetrahydrocannabinol 
(“THC”) which is the compound responsible for the psychoactive effect of cannabis. The 
potency of cannabis increased from less than 2% in 1980 to 4.5% in 1997 and 8.5% in 20069. 
In 2015, as reported by several laboratories in the U.S., a random sample of cannabis seized by 
                                                             
6 https://www150.statcan.gc.ca/n1/pub/13-610-x/cannabis-eng.htm 
7 https://www.statista.com/forecasts/745858/favorite-beer-type-of-us-beer-drinkers 
8 Richard Cowan, "How the Narcs Created Crack," National Review, December 5, 1986, pp. 30-31. 
9 University of Mississippi, National Center for Natural Products Research, Research Institute of Pharmaceutical 
Sciences. Quarterly Report #134, Potency Monitoring Program (September 2016). 
the Drug Enforcement Administration (“DEA”) was found to contain a THC potency of above 
20%10. 
• Cannabis as a Substitute of Alcohol 
A joint research study done by researchers at the University of Connecticut and Georgia State 
University between 2006 and 2015, used Nielsen Retail Scanner alcohol sales data from 90 
alcohol chain stores to compare alcohol sales in states where medical cannabis was legal versus 
states where it was not, before and after the implementation of these laws. The study accounted 
for demographic and economic variables as this has a strong impact on alcohol consumption. 
The result indicates that countries having legalised medical cannabis experienced a 13% 
decrease in alcohol sales. This study underlines the correlation between cannabis and alcohol 
and points to a strong substitution11. This method of data analysis is preferred because surveys 
are considered to be more unreliable due to a higher rate of individuals not being honest about 
their alcohol consumption. Based on this, we believe that the substitution will be stronger when 
comparing recreational cannabis to alcohol due to the increased accessibility of consumers to 
the product.  
• The Cannabis Infused Beverage Market 
The Constellation Brands Inc. (“Constellation Brands”) investment in Canopy Growth 
Corporation (“Canopy Growth”) was the biggest investment transaction in the cannabis 
industry so far and it highlighted confidence in the potential of the product for investors. More 
so, it created a new market opportunity: entering the beverage industry. While other joint 
ventures have emerged, we believe this one to offer higher value. This is because the product 
development occurs in-house with the help of the beverage giant, Constellation Brands, in 
                                                             
10 https://www.dea.gov/sites/default/files/2018-07/dir-ndta-unclass.pdf 
11 Michele Baggio, Alberto Chong, and Sungoh Kwon. Helping settle the marijuana and alcohol debate: Evidence 
from scanner data. Working paper, 2017. https://ssrn.com/abstract=3063288. 
opposition to other ventures which establish a supply chain from the cannabis producing 
company to the beverage manufacturer, thereby obtaining smaller margins for the value-added 
product. We note that the Cannabis Act12 prohibits infusing alcohol beverages with 
psychoactive compounds (THC). Based on the observed trends of decline in beer and soft drinks 
sales and healthier preference, cannabis companies are currently looking at targeting the 
demand by developing cannabis infused drinks with low degree THC potency, with lower 
calories than light beer but with similar effects to alcohol, a pleasant taste and no negative side 
effects on health. We believe this type of products will gain traction in Canada, as it did in 
Colorado, where according to Flowhub LLC (a cannabis software company which tracks 
cannabis sales), sales of cannabis infused drinks almost doubled in 2017 and were up an 
additional 18% in the first 6 months of 201813.  
• Canopy Growth Involvement 
We are of the opinion that Canopy Growth is at the forefront of this potentially high margin 
market. With Constellation Brands as a partner and its large cash injection, the Company has 
the ability to capture a new large demographic base of consumers, which will have shifted from 
beer consumption to cannabis infused beverages.  
Given that the beer industry was valued at US$ 6.7 billion in 2017 (C$ 9.0 billion) and assuming 
a cannibalization rate of 25% over the long term, we believe this industry will result in an 
additional C$ 2.25 billion to the recreational market by 2025. Assuming Canopy Growth would 
keep the same market share assumption (20% in 2025), that the average daily consumption and 
wholesale price remain the same this would add 2.4 million of consumers, which would be 
reflected in our bullish scenario at a 10% consumer growth. 
                                                             
12 https://laws-lois.justice.gc.ca/eng/acts/C-24.5/ 
13 https://www.bloomberg.com/news/articles/2018-10-10/the-next-big-thing-is-weed-beer 
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Canopy Growth Corporation’s ability to generate value from its medical cannabis segment is 
dependent on two factors: medical sales of cannabis products such as dried flowers, oil solutions 
and softgel capsules to patients and the company’s ability to generate specialised  compounds to 
compete with the ones provided by the pharmaceutical industry. In this report, we will examine 
the latter by analysing the potential size of the pharmaceutical drug industry and the possible 
disruptions that cannabis-based drugs may have in this field. 
With the world population ageing at a fast rate and with diseases such as cancer and diabetes 
becoming more prevalent, the pharmaceutical industry will continue to play an important role, 
both socially and economically. Today, according to the American Cancer Society, a voluntary 
health organisation, the risk of person in the U.S. developing cancer throughout their lifetime is 
38-40%1, while diabetes is projected to affect 15% of the U.S. population by 20302. 
At present, the pharmaceutical industry generates approximately US$1 trillion yearly3, its ten 
primary activities being: oncology (US$81.1 billion), pain (US$76.1 billion), antidiabetics 
(US$72.2 billion), autoimmune diseases (US$47.5 billion), cardiovascular (US$40.6 billion), 
respiratory (US$38.5 billion), antibiotics and vaccines (US$38.3 billion), mental health (US$36.1 
billion), HIV antivirals (US$26.7 billion), antivirals (US$23.8 billion)4. 
The legalisation of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) and more than 100 
other cannabinoids for medical purposes, could lead to structural changes in medical products in 
all of the above mentioned sectors. The main cannabinoids currently being researched are Delta-9 
THC, CBD, CBC, CBG, CBGA, CBN, THCA and CBDA and they are believed to have potential 
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therapeutic effects for Alzheimer’s disease, anorexia, arthritis, cachexia, cancer, chronic pain, 
Crohn’s disease, epilepsy, glaucoma, hepatitis C, HIV, inflammation, migraines, multiples 
sclerosis, nausea, nervous system degeneration, Parkinson’s disease, PTSD, spasms, anxiety, 
depression, insomnia and others. The effectiveness of cannabis for some of these conditions, such 
as epilepsy, seizures, multiple sclerosis, spasticity and neuropathic pain5 has been empirically 
substantiated while for others, hard evidence is still lacking.  
• The Prescription Drugs Market 
Prescription sales worldwide reached a value of US$789 billion in 20176, with the leading market 
companies being Pfizer, Novartis, Roche, Merck & Co, Johnson and Johnson, Sanofi and 
GlaxoSmithKline. These companies were responsible for 33.1% of the sales and the top 15 
companies were responsible for 54.4% of the sales7. However, the Herfindahl-Hirschman Index, 
a measure of dispersion, for the top 15 companies is only at 2.2%, meaning that the market shares 
are fairly well dissipated among these players. To put these numbers in perspective, we estimate 
the global cannabis market in 2019 at US$603 million and at US$11 billion in 2025. This latter 
figure comprises merely 1.4% of 2017’s prescription sales figures, while the 2017 figure represents 
0.08%. 
• The Painkiller Drugs Market 
Science distinguishes four types of pain: nociceptor, inflammatory, neuropathic and dysfunctional. 
In general, nociceptor and inflammatory pain of low degree can be treated with over-the-counter 
drugs, thus we believe it is unlikely for the cannabis industry to tap into this segment. Typically, 
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more severe pain is treated with opioid drugs. This is problematic as opioid drugs are greatly 
addictive and contain high levels of toxicity, which can lead to permanent kidney and liver damage 
if used recurrently. This is evidenced by data accounting for 218,000 deaths in the U.S. from 1999 
to 2017, due to overdoses related to prescription opioids8. Contrarily, cannabis-based drugs have 
low toxicity9, thus providing an alternative which is less damaging for vital organs and has a 
decreased likelihood of addiction.  
Given the social and economic externalities of opioid medicine, political momentum is building 
up for cannabinoid drugs, however, the success of these drugs depends on the quantity and quality 
of clinical trials being. Currently, clinical trials for cannabinoid active pharmaceutical component 
(“API”) are still lagging considerably when compared to opioid APIs. According to the U.S 
National Library of Medicine, at least 1543 opioid-based clinical trials are currently on the pipeline 
compared to only 212 cannabinoid-based clinical trials10. 
• Tapping into the Traditional Pharmaceutical Drugs Market 
In order to forecast the potential of the medical cannabis industry, we will use third-party forecasts 
from some of the most relevant pharmaceutical segments and extrapolations and estimates of the 
cannabis drugs penetration into those sectors. However, it is highly challenging to obtain forecasts 
and datapoints from the same sources as each source projects and defines the segments using 
different methods and timings. 
The global prescription market is forecasted to reach US$1.204 trillion in 2024, from US$789 
billion in 2017 resulting in a compounded average growth rate (“CAGR”) of 6.4%11. Medical 
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opioids, used to combat pain, generated global sales of US$27.5 billion in 201712, comprising 3% 
of the global prescription market. Using the same 3% weight and extrapolating the CAGR until 
2025, the equivalent opioid market in 2028 would be at US$53.8 billion. Using experts’ estimates, 
we have forecasted insomnia, epilepsy and antidepressants global sales at US$30.5 billion (6.5 % 
CAGR from 2017), US$ 6.1 billion (4% CAGR from 2017) and US$ 13.4 billion (1.8% CAGR 
from 2017), respectively, in 2025. 
In the event that hard evidence substantiates the effects of cannabis in treating the above mentioned 
disorders, we project cannabinoid drugs to conquer 20% of global sales of the four segments 
mentioned above in 2025. In this scenario, cannabinoid drug sales would reach US$12.82 billion. 
In our Equity Research, we have valued the global cannabis medical market to reach US$11.04 
billion in 2025. However, according to New Frontier Data, an analytics company specialising in 
the cannabis industry, the above segments were linked to just 9.2% of total cannabis prescriptions 
in Canada in 201813. This suggests that the medical cannabis market would be more valuable than 
our expected calculations. Nevertheless, due to the lengthy process of clinical trials and the time 
it takes for health practitioners to familiarise themselves with cannabis prescriptions, we believe 
that this much larger market value will only materialise itself in the long run. 
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